Immutep Ltd Share Price Today: Live Updates & Key Insights

Immutep Ltd share price today is $0.3921, up -4.34%. The stock opened at $0.3941 against the previous close of $0.4126, with an intraday high of $0.3991 and low of $0.3764.

Immutep Ltd Share Price Chart

Immutep Ltd

us-stock
To Invest in {{usstockname}}
us-stock

Immutep Ltd Share Price Performance

$0.3921 -0.0434(-4.34%) IMMP at 23 Mar 2026 01:38 PM Biotechnology
Lowest Today 0.3764
Highest Today 0.3991
Today’s Open 0.3941
Prev. Close 0.4126
52 Week High 3.32
52 Week Low 0.38
Day’s Range: Low 0.3764 High 0.3991
52-Week Range: Low 0.38 High 3.32
1 day return -
1 Week return -17.11
1 month return -86.71
3 month return -86.23
6 month return -77.57
1 year return -79.39
3 year return -79.16
5 year return -87.07
10 year return -

Immutep Ltd Institutional Holdings

iShares Biotechnology ETF 0.57

BlackRock Inc 0.39

Meridian Wealth Management, LLC 0.31

Sender Co & Partners, Inc. 0.15

Morgan Stanley - Brokerage Accounts 0.11

Millennium Management LLC 0.07

Two Sigma Investments LLC 0.06

Susquehanna International Group, LLP 0.05

Verition Fund Managegment, LLC 0.04

LPL Financial Corp 0.02

XTX Topco Ltd 0.02

Dimensional Fund Advisors, Inc. 0.02

Hilton Capital Management, LLC 0.02

Jane Street Group LLC 0.02

Virtu Financial LLC 0.02

Rhumbline Advisers 0.02

Fortitude Advisory Group L.L.C. 0.02

UBS Group AG 0.02

Marshall Wace Asset Management Ltd 0.02

Group One Trading, LP 0.01

Fidelity Nasdaq Composite Index 0.01

Geode Capital Management, LLC 0.01

Brighthouse/Dimensional Intl Sm Cm A 0.01

DFA International Core Equity 2 I 0.00

DFA International Core Equity Class F 0.00

LVIP Dimensional Intl Core Eq Std 0.00

DFA Intl Sustainability Core 1 0.00

Immutep Ltd Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Immutep Ltd Fundamentals

Market Cap 58.17 M

PB Ratio 0.8649

PE Ratio 0.0

Enterprise Value -16.18 M

Total Assets 156.98 M

Volume 1439280

Immutep Ltd Company Financials

Annual Revenue FY25:5043774 5.0M, FY24:3841877 3.8M, FY23:170369 0.2M, FY22:170369 0.2M, FY21:3968133 4.0M

Annual Profit FY25:-56366759 -56.4M, FY24:-37704847 -37.7M, FY23:null 0.0M, FY22:170369 0.2M, FY21:3968133 4.0M

Annual Net worth FY25:-61434165 -61.4M, FY24:-42716625 -42.7M, FY23:-39896348 -39.9M, FY22:-32210826 -32.2M, FY21:-29902624 -29.9M

Quarterly Revenue Q2/2025:1896103 1.9M, Q3/2024:1731134 1.7M, Q2/2024:1731134 1.7M, Q4/2023:2110743 2.1M, Q3/2023:1820188 1.8M

Quarterly Profit Q2/2025:-34183766 -34.2M, Q3/2024:-19379132 -19.4M, Q2/2024:-19379132 -19.4M, Q4/2023:1114955 1.1M, Q3/2023:896169 0.9M

Quarterly Net worth Q2/2025:-39056736 -39.1M, Q3/2024:-21488434 -21.5M, Q2/2024:-21488434 -21.5M, Q4/2023:-21228191 -21.2M, Q3/2023:-19273098 -19.3M

About Immutep Ltd & investment objective

Company Information Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Organisation Biotechnology

Employees 0

Industry Biotechnology

CEO Mr. Marc Voigt

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Immutep Ltd FAQs

What is the share price of Immutep Ltd today?

The current share price of Immutep Ltd is $0.3921.

Can I buy Immutep Ltd shares in India?

Yes, Indian investors can buy Immutep Ltd shares by opening an international trading and demat account with Motilal Oswal.

How to buy Immutep Ltd shares in India?

You can easily invest in Immutep Ltd shares from India by:

Can I buy fractional shares of Immutep Ltd?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Immutep Ltd?

Immutep Ltd has a market cap of $58.17 M.

In which sector does Immutep Ltd belong?

Immutep Ltd operates in the Biotechnology sector.

What documents are required to invest in Immutep Ltd stocks?

To invest, you typically need:

What is the PE and PB ratio of Immutep Ltd?

The PE ratio of Immutep Ltd is N/A and the PB ratio is 0.86.